Heo Sumin, Butler Andrew S, Stamouli Simoncioni Marina, Moult Sam, Malamatari Maria, Kerwash Essam, Cole Susan
Medicines and Healthcare products Regulatory Agency (MHRA), London, United Kingdom.
Department of Analytical, Environmental and Forensic Sciences, King's College London, London, United Kingdom.
Front Pharmacol. 2024 Nov 29;15:1507551. doi: 10.3389/fphar.2024.1507551. eCollection 2024.
A significant proportion of mothers take medication during the breastfeeding period, however knowledge of infant safety during continued breastfeeding is often limited. Breastmilk exhibits significant physiological heterogeneity, with a range of milk fat (creamatocrit), protein and pH values available within the literature. Mathematical models for the prediction of infant exposure are available and these predict that variable milk physiology will significantly affect accumulation of drugs within the breastmilk. These models are typically validated against limited datasets only, and to the best of our knowledge no widescale review has been conducted which accounts for the heterogeneity of breastmilk.
Observed area under the curve milk-to-plasma (M/P) ratios and physicochemical properties were collected for a diverse range of drugs. The reliability of previously published mathematical models was assessed by varying milk pH and creamatocrit across the physiological range. Subsequently, alternative methods for predicting lipid and protein binding within the milk, and the effect of ionisation and physicochemical properties were investigated.
Existing models mis-predicted >40% of medications (Phase Distribution model), exhibited extreme sensitivity to milk pH (Log-Transformed model) or exhibited limited sensitivity to changes in creamatocrit (LogP model). Alternative methods of predicting distribution into milk lipids moderately improved predictions, however altering the way in which milk protein binding was predicted and the effect of ionisation on this demonstrated little effect. Many drugs were predicted to have a significant range of M/P ratios.
These data show that consideration of the biological heterogeneity of breastmilk is important for model development and highlight that increased understanding of the physiological mechanisms underlying distribution within the milk may be essential to continue improving methodologies to support infant and maternal health.
很大一部分母亲在哺乳期会服用药物,然而对于持续母乳喂养期间婴儿安全性的了解往往有限。母乳表现出显著的生理异质性,文献中给出了一系列乳脂(乳脂比)、蛋白质和pH值。有预测婴儿暴露量的数学模型,这些模型预测可变的乳汁生理状况将显著影响药物在母乳中的蓄积。这些模型通常仅根据有限的数据集进行验证,据我们所知,尚未进行过考虑母乳异质性的大规模综述。
收集了多种药物的乳汁-血浆曲线下面积比(M/P)及理化性质的观察数据。通过在生理范围内改变乳汁pH值和乳脂比,评估先前发表的数学模型的可靠性。随后,研究了预测乳汁中脂质和蛋白质结合的替代方法,以及电离和理化性质的影响。
现有模型对超过40%的药物预测错误(相分布模型),对乳汁pH值表现出极高的敏感性(对数转换模型),或对乳脂比变化的敏感性有限(LogP模型)。预测药物在乳汁脂质中分布的替代方法适度改善了预测结果,然而改变预测乳汁蛋白质结合的方式以及电离对此的影响效果甚微。许多药物预计具有显著范围的M/P比。
这些数据表明,考虑母乳的生物学异质性对模型开发很重要,并强调进一步了解乳汁中药物分布的生理机制对于持续改进支持母婴健康的方法可能至关重要。